CompanyAVBPNasdaqNewtown Square, PA

ArriVent BioPharma, Inc.

ArriVent develops small-molecule and antibody-drug conjugate therapeutics for cancer.

SEC EDGAR ClinicalTrials.gov ir.arrivent.com

424B4Sep 28Latest SEC filing

Aug 12Latest story

August 2026

ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater China

Aug 12Clinical readoutARR-002 ArriVent BioPharma, Inc.

ArriVent registers Phase 1 trial of ARR-002 in ovarian and endometrial cancer

Aug 10Trial updateARR-002 ArriVent BioPharma, Inc.